Clinical data | |
---|---|
Trade names | Rheumox |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 20 hours |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.033.543 |
Chemical and physical data | |
Formula | C16H20N4O2 |
Molar mass | 300.362 g·mol |
3D model (JSmol) | |
Chirality | Racemic mixture |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Azapropazone is a nonsteroidal anti-inflammatory drug (NSAID). It is manufactured by Goldshield under the tradename Rheumox.
It was available in the UK as a prescription-only drug, with restrictions due to certain contra-indications and side-effects. Azopropazone has now been discontinued in the British National Formulary.
Azapropazone has a half-life of approximately 20 hours in humans and is not extensively metabolized.
References
- "Rheumox Capsules". South Africa Electronic Package Inserts. Archived from the original on 2008-05-15. Retrieved 2008-08-18.
- "Azapropazone". Patient UK. Archived from the original on 12 April 2009.
- Jones CJ (1976). "The pharmacology and pharmacokinetics of azapropazone - a review". Current Medical Research and Opinion. 4 (1): 3–16. doi:10.1185/03007997609109277. PMID 770078.
Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA) | |
---|---|
pyrazolones / pyrazolidines | |
salicylates | |
acetic acid derivatives and related substances | |
oxicams | |
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) | |
COX-2 inhibitors (coxibs) | |
other | |
NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; WHO-Essential Medicines; withdrawn drugs; veterinary use. | |
Prostanoid signaling modulators | |||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Receptor (ligands) |
| ||||||||||||||||||||||||||
Enzyme (inhibitors) |
| ||||||||||||||||||||||||||
Others | |||||||||||||||||||||||||||
This drug article relating to the musculoskeletal system is a stub. You can help Misplaced Pages by expanding it. |